Tyrosine Kinase Inhibitor
Tuspetinib for Acute Myeloid Leukemia
This trial is testing a new drug, HM43239, for patients with relapsed or refractory acute myeloid leukemia (AML). The goal is to find the safe dose range and to see how well the drug works.
Anti-tumor antibiotic
BH-30236 for Acute Myeloid Leukemia and Myelodysplastic Syndrome
"This trial is studying a new drug for people with relapsed or refractory acute myelogenous leukemia or higher-risk myelodysplastic syndrome. The study has two phases: Phase 1
Popular Filters
Trials for Acute Promyelocytic Leukemia Patients
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Chemotherapy
CC-91633 for Leukemia
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
Trials for Megakaryoblastic Leukemia Patients
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Chemotherapy
CC-91633 for Leukemia
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
Trials for FLT3 Positive Patients
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Chemotherapy
Ziftomenib Combinations for Acute Myeloid Leukemia
This trial will test the safety and effectiveness of a drug called ziftomenib when used together with standard treatments for patients with a type of blood cancer called acute myeloid leukemia that has come back
CAR T-cell Therapy
Genetically Modified T-cell Therapy for Leukemia
This trial is testing the side effects and best dosage of genetically modified T-cells, which are a type of immune cell, in patients with leukemia or a certain type of cancer of the blood and bone marrow.
Tyrosine Kinase Inhibitor
Gilteritinib + Azacitidine for Acute Myeloid Leukemia
This trial is testing an experimental drug, ASP2215 (gilteritinib), on patients recently diagnosed with AML. AML is cancer of the bone marrow where abnormal white blood cells are produced. The trial will compare the effects of ASP2215 with the standard of care treatment, azacitidine (Vidaza®), on patients' overall survival.
Anti-metabolites
Azacitidine + Nivolumab/Midostaurin vs. Decitabine/Cytarabine for Acute Myeloid Leukemia
This trial is studying azacitidine with or without nivolumab or midostaurin, or decitabine and cytarabine alone to see how well they work compared to each other in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Trials for IDH Positive Patients
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
IDH1 Inhibitor
Ivosidenib + Azacitidine for Acute Myeloid Leukemia
This trial is testing a new oral drug, ivosidenib, combined with an injectable drug, azacitidine. It targets adults with a specific type of untreated leukemia who can't undergo intensive treatments. Ivosidenib blocks a faulty enzyme in cancer cells, and azacitidine stops these cells from growing.
IDH1 Inhibitor
AG-120 for Blood Cancers
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
IDH Inhibitor
AG-120 or AG-221 Combination Therapy for Acute Myeloid Leukemia
This trial is studying AG-120 and AG-221 to see if they are safe when given with standard AML induction and consolidation therapy and to find the maximum tolerated dose of each drug.
IDH2 Inhibitor
Enasidenib + Azacitidine for Acute Myeloid Leukemia
This trial studies enasidenib and azacitidine in patients with acute myeloid leukemia (AML) that has come back or does not respond to treatment. These patients have a specific gene mutation called IDH2. The drugs work by blocking enzymes that cancer cells need to grow. Enasidenib is approved by the US FDA for adults with relapsed or refractory AML with an IDH2 mutation.
Phase 3 Trials
IDH1 Inhibitor
Ivosidenib + Azacitidine for Acute Myeloid Leukemia
This trial is testing a new oral drug, ivosidenib, combined with an injectable drug, azacitidine. It targets adults with a specific type of untreated leukemia who can't undergo intensive treatments. Ivosidenib blocks a faulty enzyme in cancer cells, and azacitidine stops these cells from growing.
Radioimmunotherapy
Iomab-B + HCT for Acute Myeloid Leukemia
This trial is testing a new treatment for AML patients who have relapsed or are unresponsive to other treatments. The new treatment consists of a reduced intensity conditioning regimen in conjunction with Iomab-B and allogeneic hematopoietic stem cell transplant.
Tyrosine Kinase Inhibitor
Gilteritinib + Azacitidine for Acute Myeloid Leukemia
This trial is testing an experimental drug, ASP2215 (gilteritinib), on patients recently diagnosed with AML. AML is cancer of the bone marrow where abnormal white blood cells are produced. The trial will compare the effects of ASP2215 with the standard of care treatment, azacitidine (Vidaza®), on patients' overall survival.
Anti-tumor antibiotic
Chemotherapy for Acute Myeloid Leukemia in Young Patients with Down Syndrome
This trial studies a chemotherapy treatment that adjusts based on how well patients respond initially. It targets younger patients with Down syndrome who have certain types of blood cancer. The treatment aims to effectively kill cancer cells while reducing side effects.
Trials With No Placebo
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Chemotherapy
CC-91633 for Leukemia
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
View More Related Trials
Frequently Asked Questions
Introduction to acute myeloid leukemia
What are the top hospitals conducting acute myeloid leukemia research?
When it comes to cutting-edge clinical trials in the battle against acute myeloid leukemia (AML), several top hospitals are leading the way. In Houston, MD Anderson Cancer Center takes the forefront with an impressive 14 ongoing AML trials and a remarkable history of 92 completed studies dedicated to this aggressive form of leukemia. This renowned institution has been at the vanguard of AML research since recording its first trial back in 2001. Meanwhile, Massachusetts General Hospital in Boston is also making significant strides, currently conducting ten active AML trials and having accumulated a total of 70 pioneering studies since their initial trial in 2003.
Further highlighting Houston's role as a medical hub for advanced AML research, M D Anderson Cancer Center joins the ranks with ten ongoing clinical trials and an astonishing tally of 93 all-time conducted studies since their inaugural investigation on this disease began in1999.City of Hope located in Duarte demonstrates its commitment to finding novel treatments by actively engaging in nine ongoing clinical tests while contributing previous findings from thirty-eight experiments starting from its first recorded investigation on acute myeloid leukemia twenty years ago; specifically dating back until2004.Roswell Park Cancer Institute situated proudly within Buffalo exhibits dedication through nine active clinical trials addressing AMLand leaving behind landmark contribution through one hundred seven previously enrolled patients into various structured investigations ever since they commenced focused exploration targeting Acute Myeloid Leukaemia cases; evidently marking groundbreaking advances initiated around twenty-four years ago precisely pinpointed during1997.
These esteemed hospitals embody not only hope for those affected by acute myeloid leukemia but also represent triumphs of medical progress and tireless efforts towards finding effective treatments nationwide. The collaborative endeavors carried out by these leading institutions bring us closer to unraveling mysteries surrounding this complex disease and offer renewed optimism for countless patients worldwide who are battling against this challenging condition
Which are the best cities for acute myeloid leukemia clinical trials?
When it comes to acute myeloid leukemia (AML) clinical trials, several cities stand out as leading centers for research and treatment. Boston, Massachusetts, leads the pack with 48 active trials focused on studying promising treatments like AG-120, CC-90009, and cytarabine. Following closely behind are Houston, Texas; New york City; and Chicago, Illinois—all with 47 active AML trials exploring various interventions such as Venetoclax, CC-486, and B (Induction: clofarabine; Consolidation: clofarabine; Maintenance: decitabine or transplant). Saint Louis in Missouri also contributes significantly to AML research with 24 ongoing studies investigating potential breakthroughs like CC-90009 and Cytarabine. These cities serve as hubs of innovation in AML treatment options by providing access to cutting-edge clinical trials that pave the way for improved outcomes for patients.
Which are the top treatments for acute myeloid leukemia being explored in clinical trials?
Clinical trials investigating treatments for acute myeloid leukemia (AML) have identified several noteworthy candidates. Leading the pack is venetoclax, a drug that has caught researchers' attention with its involvement in eight active AML trials and an impressive track record of 130 all-time clinical trials since its introduction in 2014. Another contender, cytarabine, remains a stalwart in AML research, currently being tested in five ongoing trials and having been featured in an extensive 246 all-time AML studies since 2001. Additionally, liposome-encapsulated Daunorubicin-Cytarabine shows promise with five active and 17 all-time AML trials since it was first introduced back in 2015. Pevonedistat follows closely behind with three active and 14 all-time AML trials since entering the scene in 2016. Lastly but not leastly is CPX-351—a treatment under investigation across two current and twenty-three previous clinical trials dedicated to combating this challenging disease—first listed as a potential therapy option for patients suffering from AML way back when, specifically around the year of our Lord's grace: MMIX or more commonly known as "2009." These innovative therapies offer hope on the horizon for individuals affected by acute myeloid leukemia.
What are the most recent clinical trials for acute myeloid leukemia?
Recent clinical trials offer new hope for those suffering from acute myeloid leukemia. One such trial focuses on the use of meropenem as a treatment option, with promising results emerging from its Phase 4 stage. Additionally, another study explores dose level 1 in acute myeloid leukemia patients, aiming to determine its efficacy and potential benefits. Regimen A involving TBI/Thiotepa/Cyclophosphamide is being investigated in Phase 2 trials, offering insights into novel treatment approaches. Furthermore, GDX012 has shown promise through its dual-phase clinical trial (Phase 1 and Phase 2), investigating dose escalation strategies for improved outcomes. Lastly, an experimental therapy known as WU-NK-101 is also being explored in a Phase 1 trial setting for acute myeloid leukemia patients. These cutting-edge studies bring renewed optimism to individuals battling this challenging disease.
What acute myeloid leukemia clinical trials were recently completed?
Several recent clinical trials have made significant strides in advancing treatments for acute myeloid leukemia (AML). In June 2021, AbbVie completed a trial evaluating the efficacy of Lemzoparlimab. Pfizer also reached an important milestone in May 2021 with their Azacitidine study. Furthermore, Dubermatinib by Bhavana Bhatnagar concluded its trial in November 2020. These and other completed trials demonstrate ongoing efforts to improve treatment options for AML patients and signify promising advancements in the field.